Exact Sciences
EXAS
Market cap $9.9B

51.91 USD

-1.41

2.64%

At close Jul 11, 4:00 PM EDT

After hours

51.50

-0.41

0.79%

1 day

-2.64%

5 days

-2.84%

1 month

-6.74%

3 months

16.78%

6 months

-11.28%

Year to date

-8.82%

1 year

15.77%

5 years

-42.39%

10 years

88.35%

About: Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Employees: 7,000

Healthcare Diagnostics & Research

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

17% more call options, than puts

Call options by funds: $83.1M | Put options by funds: $71.4M

0.97% less ownership

Funds ownership: 98.74% [Q4 2024] → 97.78% (-0.97%) [Q1 2025]

9% less repeat investments, than reductions

Existing positions increased: 173 | Existing positions reduced: 191

6% less funds holding

Funds holding: 581 [Q4 2024] → 545 (-36) [Q1 2025]

23% less capital invested

Capital invested by funds: $10.3B [Q4 2024] → $7.86B (-$2.41B) [Q1 2025]

26% less first-time investments, than exits

New positions opened: 73 | Existing positions closed: 98

43% less funds holding in top 10

Funds holding in top 10: 7 [Q4 2024] → 4 (-3) [Q1 2025]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$54

4%

upside

Avg. target

$65

25%

upside

High target

$72

39%

upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

Evercore ISI Group Vijay Kumar	31%upside $68	Outperform Maintained	8 Jul 2025
Barclays Luke Sergott	25%upside $65	Overweight Maintained	24 Jun 2025
RBC Capital Gerard Cassidy	4%upside $54	Sector Perform Maintained	2 May 2025
Baird Catherine Schulte	39%upside $72	Outperform Maintained	2 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about EXAS published over the past 30 days

Zacks Investment Research

QGEN or EXAS: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Qiagen (QGEN) or Exact Sciences (EXAS). But which of these two stocks presents investors with the better value opportunity right now?

QGEN or EXAS: Which Is the Better Value Stock Right Now?

Geneoscopy Wins Patent Trial and Appeal Board Decision, Invalidating All 20 Claims of Exact Sciences' '781 Patent

ST. LOUIS, Mo.--(BUSINESS WIRE)--Geneoscopy wins PTAB ruling as all 20 claims of Exact Sciences' '781 patent are invalidated, paving the way for continued advancement of ColoSense.

Geneoscopy Wins Patent Trial and Appeal Board Decision, Invalidating All 20 Claims of Exact Sciences' '781 Patent

Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) for serial use in patients with stage II, III and resectable stage IV colorectal cancer (CRC) in the adjuvant and recurrence monitoring settings over a f.

Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer

Zacks Investment Research

What Makes Exact Sciences (EXAS) a New Buy Stock

Exact Sciences (EXAS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Exact Sciences (EXAS) a New Buy Stock

Zacks Investment Research

QGEN vs. EXAS: Which Stock Is the Better Value Option?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen (QGEN) and Exact Sciences (EXAS). But which of these two stocks offers value investors a better bang for their buck right now?

QGEN vs. EXAS: Which Stock Is the Better Value Option?

Zacks Investment Research

Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?

EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its staying power.

Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?

Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced new data to be presented from the Beta-CORRECT clinical validation study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Results from Beta-CORRECT, a subset of the GALAXY cohort, validate the performance of its tumor-informed molecular residual disease (MRD) test, Oncodetect™, in predicting recurrence in stage II–IV colorectal.

Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap

Exact Sciences to Participate in June Investor Conference

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. William Blair 45th Annual Growth Stock Conference, Chicago Presentation on Tuesday, June 3, 2025 at 9:40 a.m. ET The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. About E.

Exact Sciences to Participate in June Investor Conference

Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3, 2025, in Chicago, Ill. Presentations include new data on the Oncodetect™ molecular residual disease (MRD) test, multi-cancer early detection (MCED) testing, the Oncotype DX Breast Recurrence Score® test, and the Cologuard®.

Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025

The Motley Fool

2 Brilliant Stocks to Buy With $200 and Hold for 5 Years

While being an innovative company doesn't guarantee superior long-term returns, it doesn't hurt those chances either. In fact, when a corporation is making important breakthroughs and boasts significant growth prospects in its industry, that could translate to above-average stock market performances over five years or more.

2 Brilliant Stocks to Buy With $200 and Hold for 5 Years

See News Rankings

Charts implemented using Lightweight Charts™